奎硫平与奋乃静治疗老年精神障碍对照研究.DOCVIP

临床医学论文-奎硫平与奋乃静治疗老年精神障碍对照研究 【摘要】? 目的 探讨奎硫平治疗老年精神障碍的临床疗效及安全性。 方法 将58例老年精神障碍患者随机分为两组各29例，分别口服奎硫平与奋乃静治疗，观察6 w。于治疗前及治疗第2 w、4 w、6 w末采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。 结果 治疗6 w末，奎硫平组显效率72.4%，有效率89.6%；奋乃静组显效率68.9%，有效率86.2%；两组显效率、有效率比较均无显著性差异（P＞0.05）。阳性与阴性症状量表评分，两组治疗2 w末起，总分及各因子分均较治疗前有显著下降（P＜0.05或0.01），同期两组间比较均无显著性差异（P＞0.05）。两组不良反应多在用药早期出现，程度较轻微，患者可耐受，经相应处理可减轻或缓解。奎硫平组完全依从率（62.5%）高于奋乃静组（45.0%），但差异无显著性（χ2=1.732，P＞0.05）。 结论 奎硫平治疗老年精神障碍疗效与奋乃静相当，且安全性高、服药依从性好，可作为治疗老年期精神障碍的首选药物。 【关键词】? 老年；精神障碍；奎硫平；奋乃静 　　A control study of quetiapine and perphenazine in senile mental disorders 　　【Abstract】 Objective? To explore the efficacy and safety of quetiapine in senile mental disorders. Methods? 58 senile patients were randomly divided into quetiapine and perphenazine group（each n=29） for 6 weeks. Efficacies were assessed with the Positive and Negative Syndrome（PANSS） and adverese reactions with Treatment Emergent Symptom Scale（TESS） before treatment and at the ends of the 2nd，4th and 6th week. Results? At the end of the 6th week，excellence and effectiveness rates were 72.4% and 89.6% in the quetiapine and 68.9% and 86.2% in the perphenazine group respectively, which showed no significant differences（P0.05）. The total and each factor scores of the PANSS of both groups lowered more significantly since the end of the 2nd week compared with pretreatment（P0.05 or 0.01） and there were no significant differences in synchronization intergroup comparisons（P0.05）. Adverse reactions occurred early，were mild and tolerable, and lessened and relieved following corresponding treatment. Full compliance rate was higher of quetiapine（62.5%） than of perphenazine（45.0%） group，but the difference was not significant（P0.05）. Conclusion? Quetiapine has therapeutic equivalnece to perphenazine，higher safety and better compliance in senile mental disorders and can be used as a choice drug in the treatment of geriatric mental disorders. 　　【Keywords】? The aged；mental disorder；quetiapine；perphenazine 　　随着人口的老龄化，老年期精神障碍问题日显